Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer

Abstract

S-1 plus docetaxel combination therapy in an outpatient setting provided promising activity with acceptable adverse toxicities.

A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer

“…The median PFS was 6.5 months and median OS was 15.3 months. Twenty-four patients (53.3 %) received second-line chemotherapy [16]. In present study, PFS and OS were comparable with docetaxel plus S-1 regimen, but more patients received second-line chemotherapy.…”

Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis

“…Indeed, the current trend among most research groups is to develop strategies to individualize the use of chemotherapy in older or frail patients. Thus, trials have been conducted regarding modified oxaliplatin-based, two-drug chemotherapies(21-23) and double-agent schedules with docetaxelfluoropyrimidine (24).The feasibility of using an attenuated, three-agent scheme denominated miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) has also been evaluated in frail, older people (25). In general, all these experiences have concluded that modified schedules are efficacious and convenient in this population.…”

Inflammation-Based Prognostic Score Predicts Survival in Patients with Advanced Gastric Cancer Receiving Biweekly Docetaxel and S-1 Combination Chemotherapy

“…Each course lasted 1 month. Treatment was continued until disease progression, patient refusal or unacceptable toxicity occurred, as shown in the previous study [3]. The mean numbers of DS treatments (±SD) were 4.8 ± 2.7 (range 2–13) in 83 registered patients and 3.3 ± 1.7 (range 2–8) in 71 patients without gastrectomy.…”

“…This retrospective study included the patients in our previous phase II study [3] and a similar population treated with the same regimen. The patients were aged 37–91 years (mean ± SD = 67.7 ± 7.4), and all were preoperatively diagnosed as having gastric adenocarcinoma using imaging tools following analysis of endoscopic biopsies.…”

“…In addition, some patients suffer from the toxicities of chemotherapy [3] and the high morbidity and mortality of surgical treatments [4], so it is important to identify factors predictive of response to chemotherapy and prognostic factors for survival in these patients.…”